Equities

CRISM' Therapeutics Corp

CRISM' Therapeutics Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)9.50
  • Today's Change0.00 / 0.00%
  • Shares traded11.96k
  • 1 Year change--
  • Beta1.6804
Data delayed at least 20 minutes, as of Nov 11 2024 15:25 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CRISM Therapeutics Corporation, formerly Amur Minerals Corporation, is a British Virgin Islands-based pharmaceutical company. The Company has developed a drug delivery technology, ChemoSeed, to improve the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy. Its lead product, ChemoSeed, is a polymer the size of a grain of rice, administering irinotecan, a generic drug approved to treat brain cancer and can be implanted directly into a tumor or the resection margin following the removal of a tumor, thereby ensuring that effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. It seeks to use ChemoSeed to treat high grade gliomas, a brain tumor with no satisfactory treatment. The Company also offers formulation and consultancy services. It provides assistance and services to improve the bioavailability of poorly soluble drugs. It offers remixers and extruders of various sizes.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-349.70k
  • Incorporated2004
  • Employees4.00
  • Location
    CRISM' Therapeutics CorpKingston Chambers,, Road TownPO Box 173TORTOLA 680063Virgin Islands (British)VGB
  • Phone+7 4 212755615
  • Websitehttps://www.crismtherapeutics.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
CRTX:LSE since
announced
Transaction
value
Extruded Pharmaceuticals LtdAnnounced13 May 202413 May 2024Announced-34.03%--
Data delayed at least 20 minutes, as of Nov 11 2024 15:25 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nuformix PLC0.00-341.86k709.65k2.00--0.0999-----0.0005-0.00050.000.0050.00-------7.72---8.21--------------0.00--------------
CRISM' Therapeutics Corp0.00-349.70k3.10m4.00--1.50-----0.0408-0.04080.000.06340.00----0.00-8.18-8.91-12.38-9.27-----------1.010.00------9.04------
BSF Enterprise PLC67.24k-1.71m3.88m4.00--0.9702--57.63-0.0166-0.01660.00070.03870.01281.790.042516,810.00-32.47---34.78---44.74---2,542.56--6.17-218.850.0287-------61.40------
Oxford Biodynamics PLC617.00k-11.11m4.25m45.00--1.69--6.89-0.0643-0.06430.00350.0080.04871.200.37913,711.11-87.64-39.72-114.28-45.5241.49---1,800.32-1,324.620.6156-87.720.7873--231.17-15.53-61.34---1.60--
Kanabo Group PLC1.14m-8.18m6.70m17.00--1.13--5.88-0.013-0.0130.00180.00940.105416.2843.8567,058.82-75.70-75.83-81.16-83.337.89---718.33-1,267.352.72-63.430.0337--48.42---16.26------
Oncimmune Holdings PLC1.21m-3.14m12.42m33.00------10.23-0.04230.09580.0164-0.01720.17561.190.691736,787.88-45.43------63.34---258.65--1.01-0.65111.32--------------
Data as of Nov 11 2024. Currency figures normalised to CRISM' Therapeutics Corp's reporting currency: UK Pound GBX
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.